SCHEDULE: Samsara BioCapital Exits OnKure Therapeutics Stake

Samsara BioCapital and its affiliates have reported zero beneficial ownership in OnKure Therapeutics, Inc. Class A Common Stock as of June 30, 2025.

Summary

• Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju (collectively, "Reporting Persons") filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in OnKure Therapeutics, Inc.
• As of June 30, 2025, the Reporting Persons reported 0.00 shares beneficially owned, representing 0.0% of OnKure Therapeutics, Inc.'s Class A Common Stock.
• This filing indicates a complete divestment or reduction below the reporting threshold from their previous holdings.
• The Reporting Persons explicitly disclaim status as a "group" for the purposes of this Schedule 13G.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: The filing indicates a complete divestment by Samsara BioCapital and its affiliates, reducing their beneficial ownership to 0.0% in OnKure Therapeutics. This is generally perceived as a negative signal for the company, suggesting a lack of continued confidence from a prior institutional investor.

Positives

• Clarity on institutional ownership structure with a significant holder exiting their position.

Negatives

• Samsara BioCapital, a venture capital firm, has reduced its beneficial ownership in OnKure Therapeutics, Inc. to 0.0% as of June 30, 2025.
• The complete divestment by a significant institutional investor like Samsara BioCapital could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy regarding OnKure Therapeutics.

Risks

• The exit of a significant institutional investor may lead to decreased investor confidence and potential downward pressure on the stock price.
• Reduced institutional ownership could impact the company's ability to raise future capital or attract new institutional investors.

Future Outlook

No forward-looking statements or guidance from OnKure Therapeutics are provided in this filing, as it pertains to a change in beneficial ownership by an external investor.

Management Comments

• Reporting Persons Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju explicitly disclaim status as a 'group' for purposes of this Schedule 13G.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a change in institutional investment in the biotechnology/pharmaceutical sector. The exit of a venture capital firm like Samsara BioCapital from a therapeutics company could be part of a broader trend of portfolio rebalancing or a specific assessment of OnKure's pipeline or market position.

Comparison to Industry Standards

• The complete divestment by a venture capital firm like Samsara BioCapital is a notable event in the biotech investment landscape, as such firms typically invest for long-term growth and strategic influence. While specific comparable companies or projects are not detailed in this filing, similar exits by early-stage investors in other therapeutics companies often precede or coincide with significant company developments, whether positive or negative.

Stakeholder Impact

• Shareholders: Existing shareholders may react negatively to the news of a significant institutional investor exiting, potentially leading to a decrease in share price.
• Potential Investors: May view the exit as a red flag, making it harder for OnKure Therapeutics to attract new institutional investment.

Key Dates

Recommendation

The complete divestment by Samsara BioCapital, a venture capital firm, from OnKure Therapeutics, Inc. is a strong negative signal. Institutional exits often indicate a loss of confidence in the company's future prospects, pipeline, or strategic direction. This could lead to downward pressure on the stock price and may deter other institutional investors, suggesting a 'sell' recommendation for existing holders and caution for potential new investors.

Keywords

OnKure Therapeutics, Samsara BioCapital, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, Divestment, SEC Filing, Biotechnology